TLSA 2.06 ▼ -0.48% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Tiziana Life Sciences Ltd

    NASDAQ: TLSA · Real-Time Price · USD
    2.06
    -0.01 (-0.48%)
    At close: Sep 26, 2025, 3:59 PM
    2.02
    -1.94%
    After-hours: Sep 26, 2025, 07:44 PM EDT
    -0.48%
    Bid 1.99
    Market Cap 114.81M
    Revenue (ttm) n/a
    Net Income (ttm) -10.88M
    EPS (ttm) -0.11
    PE Ratio (ttm) -18.73
    Forward PE -12.94
    Analyst n/a
    Dividends n/a
    Ask 2.07
    Volume 306,318
    Avg. Volume (20D) 395,357
    Open 2.11
    Previous Close 2.07
    Day's Range 1.97 - 2.16
    52-Week Range 0.63 - 2.60
    Beta 0.20
    Ex-Dividend Date n/a

    About TLSA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TLSA
    Website n/a
    Full Company Profile
    3 weeks ago
    +5.06%
    TLSA stock has given up its prior gain. Tiziana Li... Unlock content with Pro Subscription
    3 weeks ago
    +5.06%
    Tiziana Life Sciences shares are trading higher after the company announced its Chairman, Gabriele Cerrone, bought 25,000 shares at $1.60 per share.
    news image

    2 days ago · proactiveinvestors.com

    Tiziana Life Sciences stock higher on inflammatory therapy plans

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that block...

    news image

    2 days ago · proactiveinvestors.com

    Tiziana to push ahead with second drug candidate in inflammation research

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer a...

    news image

    3 days ago · proactiveinvestors.com

    Tiziana to share trial design for nasal MS drug at global congress

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) is set to highlight the design of its mid-stage trial for an experimental multiple sclerosis treatment at a leading international neurology conference this week...

    news image

    1 month ago · proactiveinvestors.com

    Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system at...

    news image

    1 month ago · proactiveinvestors.com

    Tiziana Life Sciences doses first patient in Phase 2a MSA trial

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System A...

    news image

    1 month ago · proactiveinvestors.com

    Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal...

    news image

    2 months ago · proactiveinvestors.com

    Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding ...

    Add to Watchlist